Blog | HemaCare

HemaCare PBMCs Aid HPV Cancer Research

Apr 7, 2020 10:07:00 AM / by Nancy Andon, MSc posted in Cancer, PBMCs, T Cells

0 Comments

Cell therapy starting materials sourced from HemaCare are being used to support studies focused on the selective expansion of tumor-specific T cells.

In a recent article, [1] researchers at a Cambridge, MA biotech company describe their work with a fusion protein designed to specifically activate and expand killer T cells that recognize human papilloma virus associated (HPV+) head and neck cancer cells.

Read More

HemaCare PBMCs Power Exosome-based Cancer Immunotherapy

Mar 3, 2020 10:02:00 AM / by Nancy Andon, MSc posted in Cancer, PBMCs, Immunotherapy (Immunology)

0 Comments

In a recent study, scientists at UCLA medical school cited using HemaCare sourced PBMCs for their research into a novel cancer immunotherapy strategy. [1]

This promising new strategy is based on cellular structures known as exosomes, which are small membrane-bound packets used to deliver protein “messages” from cell to cell. Because exosomes are known to facilitate cell-to-cell communications, researchers were keen to figure out whether they could be used to communicate the information immune cells need to target cancer.

Read More

New T Cell Therapy Raises Hopes for Universal Cancer Treatment

Feb 25, 2020 10:12:00 AM / by Nancy Andon, MSc posted in Cancer, Cell Therapy, T Cells

0 Comments

A new type of T cell capable of recognizing and killing most human cancer cells has just been discovered. Researchers at Cardiff University in Wales hit upon the entirely new class of T cell while examining immune cells at a local blood bank. [1] This T cell carries a novel T cell receptor (TCR) which recognizes most cancers, while ignoring healthy cells.

Read More

Tests in New Immunotherapy Targets Macrophages Instead of Cancer Cells

Dec 23, 2019 10:07:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Macrophages, Immunotherapy (Immunology)

0 Comments

A collaborative team of scientists from Denmark, France, the UK, and the US recognized the potential to target CD163 macrophages for a novel approach to cancer immunotherapy.

Macrophages are one of many types of immune system cells of the body, and they function to phagocytize and digest invading substances including bacteria and other microorganisms; they also digest cellular debris and cancer cells. However, there are a subset of macrophages (CD163 macrophages) that actually supports tumor survival and impedes T-cell attack of tumors. Expression of CD163 by these macrophages is associated with a poorer prognosis for a number of human cancers, such as malignant melanoma.

Read More

Immunotherapy for Breast Cancer on the Horizon

Sep 17, 2019 10:02:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Tumors, Immunotherapy (Immunology)

0 Comments

A new treatment has been approved by the FDA to treat breast cancer that combines chemotherapy with immunotherapy.

The war against cancer is ongoing and consists of both winning and losing battles. There are several cancers that have been successfully treated with immunotherapy. However, one type of cancer has been a challenge for the application of immunotherapy is breast cancer. There are various subtypes of breast cancer, and each requires a different treatment approach due to the distinct biology associated with these cancer types and the specific mechanisms involved in breast tumor development.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts